3d
MedPage Today on MSNCan Flu Shot Nudges Lead to Fewer COVID Vaccinations?Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
19h
Investor's Business Daily on MSNAstraZeneca Stock Nears Buy Point After Long Run In Declining MarketAstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...
3d
Pharmaceutical Technology on MSNAstraZeneca and Ionis win EU approval for ATTR polyneuropathyAstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results